Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Trogarzonon Apr 05, 2023 6:49pm
109 Views
Post# 35382110

RE:Life science leader

RE:Life science leader When I read his comments, I feel like his tenure at Thera has been an expiriment and not a very succesful one at that.  The board failed at preventing the outcome we have at the moment considering his inexperience of biotech and running a public company.  The CFO was not Luc, considering the deals we got we know that now.  The IR was a priority when it was bas and has now become a liability ifor shareholders. It is destroying value at this point.  I know somebody won't agree with me of course and will verbalise it but that person is on ignore now.  My opinion is that the CEO was a rookie in some important areas of the job and that the board, CGO and IR failed us at supervising and adressing the problem.  That is why I will vote to cast the out and putt forward a new path to the futur that could be a strategic review process to sell the company.
<< Previous
Bullboard Posts
Next >>